Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2022-01-03 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease
Regulatory Filings Classification · 95% confidence The document is clearly labeled as a "PRESS RELEASE" announcing a collaboration agreement between Hansa Biopharma and AskBio regarding imlifidase and gene therapy for Pompe disease. It includes financial details (USD 5 million payment), strategic updates, and concludes with a statement indicating it is information Hansa Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation, followed by contact information for Investor Relations and Corporate Communications. This structure is characteristic of a corporate announcement intended for immediate public disclosure, often related to business development or material events, but it is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a specific shareholder vote result (DVA). Since it is a press release announcing a significant business event (collaboration/option agreement), it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), as it is a mandatory disclosure under EU regulations.
2022-01-03 English
Increase of the number of shares and votes in Hansa Biopharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'PRESS RELEASE' announcing an 'Increase of the number of shares and votes in Hansa Biopharma AB'. It details the issuance of class C shares, the resulting total number of outstanding shares, and the total number of votes. This directly relates to changes in the company's capital structure, specifically share issuance. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific corporate action regarding share capital.
2021-12-30 English
Ökning av antalet aktier och röster i Hansa Biopharma
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Hansa Biopharma dated December 30, 2021, announcing an increase in the registered share capital and the number of outstanding shares and votes due to a new issue of 440,452 C-shares. This action relates directly to capital structure changes, specifically the issuance of new shares to cover long-term incentive programs (options). This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it is a press release, the core subject matter is a specific capital event, making SHA more precise than a general RPA or RNS.
2021-12-30 Swedish
Hansa Biopharma: Emission och återköp av C-aktier för incitamentsprogram
Share Issue/Capital Change Classification · 99% confidence The document is a press release detailing a specific corporate action: the issuance (nyemission) and immediate repurchase (återköp) of C-shares related to employee incentive programs (incitamentsprogram). This action directly involves changes to the company's capital structure (issuing new shares and then buying them back) to fulfill obligations under options programs. This aligns precisely with the definition of 'Share Issue/Capital Change' (SHA) or potentially 'Transaction in Own Shares' (POS). Since the primary action described is the issuance of shares followed by a repurchase to service options, 'SHA' (Share Issue/Capital Change) is the most fitting primary category, as it covers the capital structure adjustment. However, 'POS' (Transaction in Own Shares) also covers repurchases. Given the context of issuing shares specifically to cover incentive programs, SHA is slightly broader and more appropriate for the entire transaction sequence described, although POS is also highly relevant for the repurchase part. Since the text explicitly mentions the issuance ('nyemission') and the purpose is tied to capital structure management for incentive plans, SHA is selected. The document is short and is a direct announcement, not a regulatory filing like 10-K or IR.
2021-12-09 Swedish
Hansa Biopharma: Issue and repurchase of class C shares for incentive programs
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated December 9, 2021, detailing a resolution by the board of directors to issue and immediately repurchase class C shares. This action is explicitly linked to enabling future delivery of ordinary shares under long-term incentive programs authorized by previous annual general meetings. The core subject matter is a change in the company's capital structure involving share issuance and repurchase for employee incentives. This aligns directly with the definition of 'Share Issue/Capital Change' (SHA) or potentially 'Transaction in Own Shares' (POS). Since the primary action described is the issuance of new shares followed by an immediate repurchase to facilitate incentive programs, SHA (Share Issue/Capital Change) is the most appropriate primary classification, as it involves a change in the issued share capital, even if temporary. POS focuses more narrowly on buybacks/treasury stock transactions, whereas SHA covers the broader capital structure adjustment described here. Given the context of incentive programs and capital structure, SHA is selected.
2021-12-09 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding for Hansa Biopharma AB by Handelsbanken Fonder AB. It explicitly shows the 'Before the transaction' and 'After the transaction' share counts, voting rights, and percentages. The key phrase is 'Reason for major shareholding notification Sell'. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2021-12-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.